Shrooming is the slang term for consuming psilocybin mushrooms, also called “magic mushrooms,” to experience their psychoactive effects. These mushrooms contain two key compounds, psilocybin and psilocin, that alter perception, mood, and thought patterns for roughly 3 to 6 hours. The experience can range from mild visual changes and heightened emotions at low doses to intense hallucinations and a dissolved sense of self at higher ones.
How Psilocybin Works in the Brain
When you eat psilocybin mushrooms, your body converts psilocybin into psilocin. Psilocin is the compound that actually produces the psychoactive effects. It works by activating serotonin receptors in the brain, specifically a type called 5-HT2A receptors. Serotonin is a chemical messenger involved in mood, perception, and cognition, so when psilocin stimulates these receptors, it dramatically shifts how the brain processes sensory information and emotions.
What makes psilocin different from your brain’s own serotonin is that it can pass through cell membranes and activate serotonin receptors inside neurons, not just on their surface. Research published in Science found that this intracellular activation is what drives the compound’s ability to promote new neural connections in the brain’s cortex. Serotonin itself can’t cross cell membranes the same way, which is why your brain’s natural chemistry doesn’t produce psychedelic effects.
What the Experience Feels Like
Effects typically begin within 20 to 40 minutes of eating the mushrooms and last between 3 and 6 hours total. The timeline depends on the dose, the specific mushroom species, whether you’ve eaten recently, and individual body chemistry. Most people feel the peak intensity around 60 to 90 minutes in, with a gradual tapering over the remaining hours.
At lower doses, the effects tend to be subtle: colors may appear more vivid, music might feel more emotionally resonant, and your mood can shift toward euphoria or introspection. At moderate to high doses, visual distortions become more pronounced. Surfaces may appear to breathe or ripple, geometric patterns can overlay your vision, and the boundaries between senses can blur. This blurring, called synesthesia, is surprisingly common. In studies using psilocybin, about 37% of participants reported some form of it, most often “seeing” sounds as colors or shapes. The effect is dose-dependent: at the lowest doses studied, no participants reported synesthesia, while at the highest doses, up to 50% did.
Beyond the visual effects, many people describe shifts in how they think about themselves and their lives. A sense of deep personal insight, emotional openness, or feeling connected to something larger than yourself are frequently reported. At very high doses, some people experience what’s called ego dissolution, a temporary loss of the sense of being a separate self. This can feel profound and meaningful, or it can feel deeply unsettling depending on the person’s mindset and surroundings.
Common Physical Side Effects
Shrooming isn’t purely a mental experience. Nausea is one of the most common physical complaints, especially during the first hour as the mushrooms are digested. Some people also experience dilated pupils, increased heart rate, muscle tension or twitching, yawning, and changes in body temperature. These physical effects are generally mild and subside as the experience progresses, but they can be uncomfortable, particularly the nausea.
Dosage and Potency
Over 200 species of psilocybin-containing mushrooms exist, but the most commonly encountered is Psilocybe cubensis. Others include Psilocybe semilanceata (liberty caps) and Psilocybe cyanescens. Potency varies significantly between species and even between individual mushrooms of the same species. On average, dried Psilocybe cubensis contains about 1% psilocybin by weight, though this can range from trace amounts up to 2%.
Using dried Psilocybe cubensis as a reference point, clinical researchers have established rough dose categories. Around 2.5 grams of dried mushroom is considered a standard dose, equivalent to 25 mg of pure psilocybin, which is the dose most commonly used in clinical trials. A high dose is around 3.5 grams, and anything in the 5 to 6 gram range is considered very high. Because potency varies so much, these numbers are approximations. Two batches of the same species can produce noticeably different experiences at the same weight.
Risks and Potential Harms
Psilocybin mushrooms have a low toxicity profile compared to many other substances, and fatal overdoses are extremely rare. The primary risks are psychological rather than physical. A “bad trip,” characterized by intense anxiety, paranoia, confusion, or panic, is the most commonly reported negative outcome. These experiences are more likely at higher doses, in unfamiliar or uncomfortable environments, or when the person is already in a stressed or anxious mental state.
A rarer but more concerning risk is Hallucinogen Persisting Perception Disorder (HPPD), a condition where visual disturbances from the drug experience continue long after the substance has left your body. These can include seeing halos around objects, trailing images, or visual “snow.” HPPD comes in two forms: a milder version involving brief, benign flashbacks that don’t significantly disrupt daily life, and a more severe, long-lasting form that can be distressing and slow to resolve. The DSM-5 suggests a prevalence rate of about 4.2%, though actual numbers are uncertain because the condition is frequently unrecognized. People with a history of psychological issues or substance misuse appear to be at higher risk, but HPPD can develop in anyone, even after a single use.
Misidentification is another serious danger. Since many mushroom species look alike, foraging for wild psilocybin mushrooms carries the risk of accidentally consuming a toxic species, some of which can cause organ failure or death.
Interactions With Medications
If you take psychiatric medications, the interaction with psilocybin is worth understanding. SSRIs, the most commonly prescribed antidepressants, appear to dampen some of psilocybin’s negative effects (anxiety, distressing ego dissolution) without fully blocking the positive mood changes. In one controlled study, two weeks of the SSRI escitalopram before a 25 mg psilocybin dose reduced the bad effects while leaving the positive ones largely intact.
Antipsychotic medications, which block serotonin 2A receptors, tend to significantly reduce or block psilocybin’s effects altogether. Risperidone, for example, diminishes the experience in a dose-dependent way. The anti-anxiety medication buspirone, which acts on a different serotonin receptor, markedly reduces visual distortions from psilocybin. These interactions mean the experience can be unpredictable for anyone on psychiatric medications, and the effects may be weaker, stronger, or qualitatively different than expected.
Legal Status in the United States
Psilocybin remains a Schedule I controlled substance under federal law, making possession, sale, and manufacture illegal throughout the United States. However, a patchwork of state and local laws has created exceptions in certain areas.
Oregon became the first state to legalize psilocybin-assisted therapy in 2020, with licensed service centers now operating. Colorado followed in 2022, passing Proposition 122 to legalize and regulate psychedelic treatment centers. New Mexico signed the Medical Psilocybin Act into law in April 2025, aiming to launch its access system by late 2026. Several other states have created more limited pilot programs: Utah authorized hospitals to offer psilocybin treatments in 2024, Washington established a program for veterans and first responders in 2023, and New Jersey signed a hospital-based pilot program into law in early 2026.
At the city level, Denver became the first U.S. city to deprioritize law enforcement for psilocybin possession in 2019. Since then, cities including Oakland, Santa Cruz, San Francisco, Ann Arbor, Detroit, Seattle, Minneapolis, and several others in Massachusetts and Washington have passed similar measures making personal possession the lowest police priority. Deprioritization doesn’t make possession legal. It simply means local police are directed not to spend resources investigating or arresting people for it.
The FDA has granted breakthrough therapy designations to multiple organizations studying psilocybin for treatment-resistant depression and major depressive disorder, signaling that the agency considers the evidence promising enough to accelerate review. These designations do not make psilocybin legal for general use but reflect growing institutional recognition of its therapeutic potential.